Adult T-cell leukemia-lymphoma

Back to Top
Are you looking for a regimen, but can't find it here? It is possible that we've moved it to the historical regimens page.
Last updated on 2024-07-23:5 regimens on this page
5 variants on this page
*We have moved How I Treat articles to a dedicated page.
=Guidelines=
Given the rapid change in evidence in many areas of hematology/oncology, readers are encouraged to consider any guideline published 5+ years ago to be for historical purposes, only.
==NCCN==
*NCCN does not currently have guidelines at this granular level; please see NCCN Guidelines - T-cell Lymphomas.
=Untreated=
==CHOP-14==
CHOP-14: Cyclophosphamide, Hydroxydaunorubicin (Doxorubicin), Oncovin (Vincristine), Predniso(lo)ne every 14 days
CHOP-DI: Cyclophosphamide, Hydroxydaunorubicin (Doxorubicin), Oncovin (Vincristine), Predniso(lo)ne, Dose-Intense
I-CHOP: Intensive Cyclophosphamide, Hydroxydaunorubicin (Doxorubicin), Oncovin (Vincristine), Predniso(lo)ne
===Regimen===
Study 	Dates of enrollment	Evidence 	Comparator 	Comparative Efficacy 	Comparative Toxicity
Itoh et al. 2002 (JCOG 9505) 	1995-1998 	Randomized Phase 2 (E-de-esc)	dose-escalated CHOP	Did not meet primary endpoint of CR rate	Less toxic
Tsukasaki et al. 2007 (JCOG 9801)	1998-2003 	Phase 3 (C) 	mLSG15 	Did not meet primary endpoint of OS 	Less toxic
====Chemotherapy====
*Cyclophosphamide (Cytoxan) 750 mg/m2 IV once on day 1
*Doxorubicin (Adriamycin) 50 mg/m2 IV once on day 1
*Vincristine (Oncovin) 1.4 mg/m2 (maximum dose of 2 mg) IV once on day 1
====Glucocorticoid therapy====
*Prednisone (Sterapred) 100 mg PO once per day on days 1 to 5
====Supportive therapy====
*Filgrastim (Neupogen) given once ANC decreased to less than 1000/μL and continued once per day until count increased to greater than 5000/μL
14-day cycle for 8 cycles
====CNS therapy====
Intrathecal triple-therapy was given during recovery phase of cycles 1, 3, and 5 after platelet count was greater than 70 x 109/L.
*Cytarabine (Ara-C) 40 mg IT 
*Methotrexate (MTX) 15 mg IT
*Prednisone (Sterapred) 10 mg IT
3 doses, total
===References===
# JCOG 9505: Itoh K, Ohtsu T, Fukuda H, Sasaki Y, Ogura M, Morishima Y, Chou T, Aikawa K, Uike N, Mizorogi F, Ohno T, Ikeda S, Sai T, Taniwaki M, Kawano F, Niimi M, Hotta T, Shimoyama M, Tobinai K; JCOG. Randomized phase II study of biweekly CHOP and dose-escalated CHOP with prophylactic use of lenograstim (glycosylated G-CSF) in aggressive non-Hodgkin's lymphoma: Japan Clinical Oncology Group Study 9505. Ann Oncol. 2002 Sep;13(9):1347-55. link to original article EuroPMC
# JCOG 9801: Tsukasaki K, Utsunomiya A, Fukuda H, Shibata T, Fukushima T, Takatsuka Y, Ikeda S, Masuda M, Nagoshi H, Ueda R, Tamura K, Sano M, Momita S, Yamaguchi K, Kawano F, Hanada S, Tobinai K, Shimoyama M, Hotta T, Tomonaga M; JCOG. VCAP-AMP-VECP compared with biweekly CHOP for adult T-cell leukemia-lymphoma: Japan Clinical Oncology Group Study JCOG9801. J Clin Oncol. 2007 Dec 1;25(34):5458-64. Epub 2007 Oct 29. link to original article dosing details in manuscript have been reviewed by our editors EuroPMC NCT00145002
==mLSG15==
===Regimen===
Study 	Dates of enrollment	Evidence 	Comparator 	Comparative Efficacy
Tsukasaki et al. 2007 (JCOG 9801) 	1998-2003 	Phase 3 (E-esc) 	CHOP-14 	Did not meet primary endpoint of OS
Ishida et al. 2015 (Kyowa 0761-003)	2010-2011 	Randomized Phase 2 (C)	mLSG15 & Mogamulizumab	Did not meet primary endpoint of CR rate
Note: Ranimustine is not available in the United States and is approved only in Japan.
====Chemotherapy====
*Vincristine (Oncovin) 1 mg/m2 (maximum dose of 2 mg) IV once on day 1
*Cyclophosphamide (Cytoxan) 350 mg/m2 IV once on day 1
*Doxorubicin (Adriamycin) 40 mg/m2 IV once on day 1, then 30 mg/m2 IV once on day 8
*Ranimustine (Cymerin) 60 mg/m2 IV once on day 8
*Vindesine (Eldisine) 2.4 mg/m2 IV once on day 15
*Etoposide (Vepesid) 100 mg/m2 IV once per day on days 15 to 17
*Carboplatin (Paraplatin) 250 mg/m2 IV once on day 15
====Glucocorticoid therapy====
*Prednisone (Sterapred) 40 mg/m2 PO once per day on days 1, 8, 15 to 17
28-day cycle for 6 cycles
====CNS therapy, prophylaxis====
*Cytarabine (Ara-C) 40 mg IT, admixed with MTX & prednisone
*Methotrexate (MTX) 15 mg IT, admixed with Ara-C & prednisone
*Prednisone (Sterapred) 10 mg IT, admixed with Ara-C & MTX
Given after cycles 1, 3, and 5 after platelets greater than 70 x 109/L and within 2 days before the next cycle
===References===
#JCOG 9801: Tsukasaki K, Utsunomiya A, Fukuda H, Shibata T, Fukushima T, Takatsuka Y, Ikeda S, Masuda M, Nagoshi H, Ueda R, Tamura K, Sano M, Momita S, Yamaguchi K, Kawano F, Hanada S, Tobinai K, Shimoyama M, Hotta T, Tomonaga M; JCOG. VCAP-AMP-VECP compared with biweekly CHOP for adult T-cell leukemia-lymphoma: Japan Clinical Oncology Group Study JCOG9801. J Clin Oncol. 2007 Dec 1;25(34):5458-64. Epub 2007 Oct 29. link to original article dosing details in manuscript have been reviewed by our editors EuroPMC NCT00145002
#Kyowa 0761-003: Ishida T, Jo T, Takemoto S, Suzushima H, Uozumi K, Yamamoto K, Uike N, Saburi Y, Nosaka K, Utsunomiya A, Tobinai K, Fujiwara H, Ishitsuka K, Yoshida S, Taira N, Moriuchi Y, Imada K, Miyamoto T, Akinaga S, Tomonaga M, Ueda R. Dose-intensified chemotherapy alone or in combination with mogamulizumab in newly diagnosed aggressive adult T-cell leukaemia-lymphoma: a randomized phase II study. Br J Haematol. 2015 Jun;169(5):672-82. Epub 2015 Mar 2. link to original article link to PMC article EuroPMC NCT01173887
=Relapsed or refractory=
==Alemtuzumab monotherapy==
===Regimen===
Study 	Dates of enrollment	Evidence
Sharma et al. 2016	2004-2009 	Phase 2
Note: Scheduling is timed to start on a Monday.
====Targeted therapy====
*Alemtuzumab (Campath) as follows:
**Cycle 1: 3 mg IV once on day 1, then 10 mg IV once on day 2, then 30 mg IV once per day on days 3 & 5
**Cycles 2 to 12: 30 mg IV once per day on days 1, 3, 5 (three times per week)
====Supportive therapy====
*Antibacterial prophylaxis: Trimethoprim-Sulfamethoxazole (Bactrim DS) 160/80 mg PO once per day on days 1, 3, 5 (three times per week)
*Antiviral prophylaxis: Famciclovir (Famvir) or Valganciclovir (Valcyte) once per day
*Antifungal prophylaxis: Fluconazole (Diflucan)
7-day cycle for up to 12 cycles
===References===
# Sharma K, Janik JE, O'Mahony D, Stewart D, Pittaluga S, Stetler-Stevenson M, Jaffe ES, Raffeld M, Fleisher TA, Lee CC, Steinberg SM, Waldmann TA, Morris JC. Phase II study of alemtuzumab (CAMPATH-1) in patients with HTLV-1-associated adult T-cell leukemia/lymphoma. Clin Cancer Res. 2017 Jan 1;23(1):35-42. Epub 2016 Aug 2. link to original article link to PMC article dosing details in manuscript have been reviewed by our editors EuroPMC
==Lenalidomide monotherapy==
===Regimen===
Study 	Dates of enrollment	Evidence	Efficacy
Ishida et al. 2016 (ATLL-002)	2012-2014 	Phase 2 	ORR: 42% (95% CI 23-63)
====Targeted therapy====
*Lenalidomide (Revlimid) 25 mg PO once per day
Continued indefinitely
===References===
# ATLL-002: Ishida T, Fujiwara H, Nosaka K, Taira N, Abe Y, Imaizumi Y, Moriuchi Y, Jo T, Ishizawa K, Tobinai K, Tsukasaki K, Ito S, Yoshimitsu M, Otsuka M, Ogura M, Midorikawa S, Ruiz W, Ohtsu T. Multicenter phase II study of lenalidomide in relapsed or recurrent adult T-cell leukemia/lymphoma: ATLL-002. J Clin Oncol. 2016 Dec;34(34):4086-4093. Epub 2016 Sep 30. link to original article dosing details in manuscript have been reviewed by our editors EuroPMC NCT01724177
==Valemetostat monotherapy==
===Regimen===
Study 	Dates of enrollment	Evidence
Izutsu et al. 2022 (DS3201-A-J201)	2019-11 to 2020-10 	Phase 2 (RT)
====Targeted therapy====
*Valemetostat (Ezharmia) 200 mg PO once per day on days 1 to 28, taken at least 2 hours before or at least 1 hour after a meal
28-day cycles
===References===
#DS3201-A-J201: Izutsu K, Makita S, Nosaka K, Yoshimitsu M, Utsunomiya A, Kusumoto S, Morishima S, Tsukasaki K, Kawamata T, Ono T, Rai S, Katsuya H, Ishikawa J, Yamada H, Kato K, Tachibana M, Kakurai Y, Adachi N, Tobinai K, Yonekura K, Ishitsuka K. An open-label, single-arm phase 2 trial of valemetostat for relapsed or refractory adult T-cell leukemia/lymphoma. Blood. 2023 Mar 9;141(10):1159-1168. Epub 2022 Sep 27. link to original article link to PMC article dosing details in manuscript have been reviewed by our editors EuroPMC NCT04102150
Category:Adult T-cell leukemia-lymphoma regimens
Category:Disease-specific pages
Category:Acute leukemias
Category:T-cell lymphomas
Category:T-cell leukemias